Harrow (HROW) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 07/30/24
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024Business Wire • 07/25/24
Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow ProductsBusiness Wire • 07/09/24
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract SurgeryBusiness Wire • 06/06/24
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension StudyBusiness Wire • 06/05/24
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024Business Wire • 04/25/24